Neuropace Inc.
Organization details
- Legal name
- Neuropace Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Mountain View
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NPCE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001528287
- EIN
- 22-3550230
- Wikidata ID
- Q63969967
Board of directors
-
Frank M. Fischer · DirectorSince 2023
-
Joel Becker · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Joseph Lacob · DirectorSince 2023
-
Lisa Andrade · DirectorSince 2023
-
Michael Favet · Director · Chief Executive OfficerSince 2023
-
R. Scott Huennekens · DirectorSince 2025
-
Rakhi Kumar · DirectorSince 2023
-
Renee Ryan · DirectorSince 2023
-
Uri Geiger · DirectorSince 2023
Chief executives
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
30% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Director election results
Annual meeting of June 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
71.6%
Board connections
4 of this board's directors also sit on 6 other boards. 5 are in the same sector.
-
Align Technology Inc. Same sectorvia Joseph Lacob
- via Rakhi Kumar
-
Envista Holdings Corporation Same sectorvia R. Scott Huennekens
-
Hyperfine Inc. Same sectorvia R. Scott Huennekens
-
QuidelOrtho Corporation Same sectorvia R. Scott Huennekens
-
Tenon Medical Inc. Same sectorvia Frank M. Fischer
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $399,250
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 24, 2026 | Morrell Martha Officer (CHIEF MEDICAL OFFICER) | Shares withheld for tax | −335 | $13.97 | $4,680 |
| Sep 20, 2026 | Patrick F. Williams Officer (Chief Financial Officer) | Shares withheld for tax | −1,162 | $14.28 | $16,593 |
| Sep 3, 2026 | Joel Becker Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for tax | −1,310 | $14.75 | $19,323 |
| Aug 27, 2026 | Joel Becker Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for tax | −1,126 | $14.13 | $15,910 |
| Aug 27, 2026 | Morrell Martha Officer (CHIEF MEDICAL OFFICER) | Shares withheld for tax | −358 | $14.13 | $5,059 |
| Jun 24, 2026 | Morrell Martha Officer (CHIEF MEDICAL OFFICER) | Shares withheld for tax | −335 | $16.22 | $5,434 |
| Jun 19, 2026 | Uri Geiger Director | Grant or award | +789 | $15.63 | $12,332 |
| Jun 19, 2026 | Frank M. Fischer Director | Grant or award | +1,467 | $15.63 | $22,929 |
| Jun 19, 2026 | Rakhi Kumar Director | Grant or award | +989 | $15.63 | $15,458 |
| Jun 5, 2026 | R. Scott Huennekens Director | Grant or award | +2,890 | — | — |
| Jun 5, 2026 | Frank M. Fischer Director | Grant or award | +2,890 | — | — |
| Jun 5, 2026 | Uri Geiger Director | Grant or award | +2,890 | — | — |
| Jun 5, 2026 | Rakhi Kumar Director | Grant or award | +2,890 | — | — |
| Jun 5, 2026 | Renee Ryan Director | Grant or award | +2,890 | — | — |
| Jun 5, 2026 | Lisa Andrade Director | Grant or award | +2,890 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Neuropace Inc.
Who is the CEO of Neuropace Inc.?
Joel Becker has been Neuropace Inc.'s Chief Executive Officer since July 2023.
How many directors are on Neuropace Inc.'s board?
Neuropace Inc.'s board has 9 directors: Frank M. Fischer, Joel Becker, Joseph Lacob, Lisa Andrade, Michael Favet, R. Scott Huennekens, Rakhi Kumar, Renee Ryan and Uri Geiger.
Are Neuropace Inc. insiders buying or selling shares?
Over the last 12 months, Neuropace Inc. insiders made no open-market purchases and sold $399,250 of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="neuropace-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.